The DABRA Laser and Catheter System is designed to cross and modify a wide range of lesion morphologies, including calcific plaque, atherosclerotic lesions, and thrombotic occlusions.

The system delivers non-thermal 308 nm laser energy to ablate arterial blockages into their constituent chemical components while minimizing trauma to the vessel and reducing the risk of distal embolization.

DABRA supports vessel preparation strategies prior to adjunctive therapies such as low-pressure balloon angioplasty and stenting.

DABRA technology has been utilized in the treatment of more than 10,000 patients in the United States and Europe and has been supported by extensive physician experience in complex peripheral interventions.

The platform is supported by FDA 510(k) clearances, clinical data, manufacturing documentation, and intellectual property acquired by IEVC in 2026 from Catheter Precision, successor company to Ra Medical Systems.

Collaboration with healthcare professionals and research institutions is at the heart of our approach. By understanding the needs of clinicians and patients, we continue to refine our technologies, ensuring our innovations are not only effective but also user-friendly in real-world applications.